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2 available buffer solutions at pH = 4.0 ±0.02, pH = 7.00 ±0.02 and pH = 10.00 ±0.02. NMR spectra ( 1 H, while HEK-293 were grown in DMEM medium, both containing 10% heat-inactivated fetal bovine serum (FBS, Pan Biotech, Germany) and 1% antibiotics (penicillin/streptomycin), at 37 °C and CO 2 (5%).
Determination of antiproliferative activity. Cytotoxicity was determined using the MTT assay 1 (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). Cells were seeded in 96-well plates as monolayers with 100 μL of cell solution per well and pre-incubated for 24 h in the cell culture medium. Compounds were prepared as DMSO stock solutions that were dissolved in the culture medium and twofold serially diluted to the appropriate concentration to give a final DMSO concentration of maximum 0.5%. 100 μL of the drug solution were added to each well and the plates were incubated for another 72 h. Subsequently, MTT (5 mg/mL solution, 20 μL per well) was added to the cells and the plates were incubated for further 4 h. The culture medium was aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved in DMSO. The optical density, directly proportional to the number of surviving cells, was quantified at 590 nm using a multiwell plate reader (Molecular Devices). ).
8-((4-(2-Methoxy-2-oxoethyl)phenyl)amino)-8-oxooctanoic acid, 2
Methyl 2-(4-aminophenyl)acetate (700 mg, 4.69 mmol), suberoyl anhydride (560 mg, 3.59 mmol) and 
Methyl 2-(4-(8-((benzyloxy)amino)-8-oxooctanamido)phenyl)acetate
To a solution of 8-((4-(2-methoxy-2-oxoethyl)phenyl)amino)- 
Methyl 2-(4-(8-((benzyloxy)amino)-8-oxooctanamido)phenyl)acetic acid, 3a
Methyl 2-(4- (8-((benzyloxy) 
2-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)acetic acid, 3b
General Procedure 1
Methyl 2-(4-(8-((benzyloxy)amino)-8-oxooctanamido)phenyl)acetic acid, 3a, (500 mg, 1.21 mmol) was dissolved in DMF (6 mL) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (233 mg, 1.21 mmol).
After stirring for 10 min, the alcohol (1 equiv., 1.21 mmol) and 4-dimethylaminopyridine (30 mg, 0.24 mmol) were added and the solution stirred at 22 °C for 16 h. The solution was dropped into H 2 O (25 mL), leading to the formation of a white precipitate. The mixture was cooled in the fridge for 1 h before the precipitate was collected by filtration. The crude product was recrystallised from hot EtOAc (2 mL).
General Procedure 2
The ester compound, 4a-f,(1 equiv.) was dissolved in MeOH and 5 mol% Pd/C (0.2 equiv.) was added.
The mixture was purged with H 2 and stirred under an atmosphere of H 2 at 22 °C for 1 h. The mixture was filtered through Celite, which was rinsed with MeOH (5 mL). The MeOH fractions were combined and dried under reduced pressure.
8 
Octyl 2-(4-(8-((benzyloxy)amino)-8-oxooctanamido)phenyl)acetate, 4a

Octyl 2-(4-(8-(hydroxyamino)-8-oxooctanamido)phenyl)acetate, 5a
Octyl 2-(4- (8-((benzyloxy) C, 66.87; H, 8.91; N, 6.04. Found: C, 66.76; H, 8.98; N, 6 .02.
Decyl 2-(4-(8-(hydroxyamino)-8-oxooctanamido)phenyl)acetate, 5b
Decyl 2-(4- (8-((benzyloxy) observed due to C-F coupling; δ F (CDCl 3 ) - 80.1, -112.6, -121.5 (4F), -121.6, -122.4, -123.1, -125 3, 3, 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 
